Hims & Hers Health is trading at €26.72, up 6.62%, with no clear company-specific catalyst identified for the September 30 move.
- Recent coverage has focused on securities class-action notices tied to the earlier FTC lawsuit, rather than a new catalyst for this session.
- Technology-led gains followed cooler inflation data, but the broader risk-on context does not establish the cause of this stock move.
- Intraday volume and activity level are not available in the provided price context.